Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Replimune Group, Inc. | Chief Business Officer | Common Stock | 263K | $2.88M | $10.92 | Sep 12, 2023 | Direct |
Replimune Group, Inc. | Chief Business Officer | Employee Stock Option (right to buy) | 86K | Sep 12, 2023 | Direct | ||
Kymera Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 16K | Jun 18, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KYMR | Kymera Therapeutics, Inc. | Jun 18, 2024 | 1 | $0 | 4 | Jun 20, 2024 | Director |
REPL | Replimune Group, Inc. | Sep 11, 2023 | 6 | -$94.5K | 4 | Sep 13, 2023 | Chief Business Officer |
REPL | Replimune Group, Inc. | Aug 22, 2023 | 5 | -$250K | 4 | Aug 24, 2023 | Chief Business Officer |
REPL | Replimune Group, Inc. | Aug 11, 2023 | 3 | -$23.4K | 4 | Aug 15, 2023 | Chief Business Officer |
REPL | Replimune Group, Inc. | Jul 10, 2023 | 6 | -$305K | 4 | Jul 11, 2023 | Chief Business Officer |
KYMR | Kymera Therapeutics, Inc. | Jun 15, 2023 | 1 | $0 | 4 | Jun 20, 2023 | Director |
REPL | Replimune Group, Inc. | May 16, 2023 | 1 | -$108K | 4 | May 18, 2023 | Chief Business Officer |
REPL | Replimune Group, Inc. | Apr 1, 2023 | 2 | $0 | 4 | Apr 4, 2023 | Chief Business Officer |
REPL | Replimune Group, Inc. | Dec 9, 2022 | 3 | -$360K | 4 | Dec 13, 2022 | Chief Business Officer |
KYMR | Kymera Therapeutics, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 16, 2022 | Director |
REPL | Replimune Group, Inc. | May 16, 2022 | 1 | -$51.2K | 4 | May 18, 2022 | Chief Business Officer |
REPL | Replimune Group, Inc. | Apr 1, 2022 | 2 | $0 | 4 | Apr 5, 2022 | Chief Business Officer |
REPL | Replimune Group, Inc. | Aug 4, 2021 | 6 | -$587K | 4 | Aug 6, 2021 | Chief Business Officer |
REPL | Replimune Group, Inc. | Jul 20, 2021 | 6 | -$559K | 4 | Jul 22, 2021 | Chief Business Officer |
REPL | Replimune Group, Inc. | Jul 15, 2021 | 3 | -$149K | 4 | Jul 19, 2021 | Chief Business Officer |
KYMR | Kymera Therapeutics, Inc. | Jun 16, 2021 | 1 | $0 | 4 | Jun 17, 2021 | Director |
REPL | Replimune Group, Inc. | Jan 14, 2021 | 10 | -$2.36M | 4/A | Jul 19, 2021 | Chief Business Officer |